Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer

Science Translational Medicine

Volumn 4, Issue 137, 2012, Pages

  Biot, Claire ^a,b,c   Rentsch, Cyrill A ^a,b,d   Gsponer, Joel R ^a,b,d   Birkhäuser, Frédéric D ^e   Jusforgues Saklani, Hélène ^a,b   Lemaître, Fabrice ^a,f   Auriau, Charlotte ^a,b   Bachmann, Alexander ^e   Bousso, Philippe ^a,f   Demangel, Caroline ^a   Peduto, Lucie ^a   Thalmann, George N ^e   Albert, Matthew L ^a,b,g  

^a INSTITUT PASTEUR   (France)

^b INSERM   (France)

^c PSL RESEARCH UNIVERSITY   (France)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e UNIVERSITY OF BERN   (Switzerland)

^f INSTITUT PASTEUR   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; GAMMA INTERFERON;

ADAPTIVE IMMUNITY; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER IMMUNIZATION; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; CANCER SURGERY; CANCER SURVIVAL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; LYMPHATIC DRAINAGE; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; REPEATED DRUG DOSE; SINGLE DRUG DOSE; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; TUMOR IMMUNITY; ANIMAL; BLADDER TUMOR; C57BL MOUSE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOLOGY; IMMUNOTHERAPY; INNATE IMMUNITY; INTRAVESICAL DRUG ADMINISTRATION; METHODOLOGY; T LYMPHOCYTE;

ADMINISTRATION, INTRAVESICAL; ANIMALS; BCG VACCINE; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY; MICE; MICE, INBRED C57BL; T-LYMPHOCYTES; URINARY BLADDER NEOPLASMS;

EID: 84862132424     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3003586     Document Type: Article

References (51)

1. A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, D. Forman, Global cancer statistics. CA Cancer J. Clin. 61, 69-90 (2011).
2. M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, J. Palou-Redorta, M. Rouprêt; European Association of Urology (EAU), EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur. Urol. 59, 997-1008 (2011).
3. A. Morales, D. Eidinger, A. W. Bruce, Intracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J. Urol. 116, 180-183 (1976).
4. P. Gontero, A. Bohle, P. U. Malmstrom, M. A. O'Donnell, M. Oderda, R. Sylvester, F. Witjes, The role of bacillus Calmette-Guérin in the treatment of non -muscle-invasive bladder cancer. Eur. Urol. 57, 410-429 (2010).
5. A. Zwerling, M. A. Behr, A. Verma, T. F. Brewer, D. Menzies, M. Pai, The BCG World Atlas: A database of global BCG vaccination policies and practices. PLoS Med. 8, e1001012 (2011).
6. J. L. Flynn, J. Chan, P. L. Lin, Macrophages and control of granulomatous inflammation in tuberculosis. Mucosal Immunol. 4, 271 -278 (2011).
7. A. M. Cooper, Cell-mediated immune responses in tuberculosis. Annu. Rev. Immunol. 27, 393-422 (2009).
8. K. B. Urdahl, S. Shafiani, J. D. Ernst, Initiation and regulation of T-cell responses in tuberculosis. Mucosal Immunol. 4, 288-293 (2011).
9. A. B. Alexandroff, S. Nicholson, P. M. Patel, A. M. Jackson, Recent advances in bacillus Calmette-Guérin immunotherapy in bladder cancer. Immunotherapy 2, 551-560 (2010).
10. S. Brandau, H. Suttmann, Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: A success story with room for improvement. Biomed. Pharmacother. 61, 299- 305 (2007).
11. T. L. Ratliff, D. Gillen, W. J. Catalona, Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. J. Urol. 137, 155-158 (1987).
12. T. L. Ratliff, J. K. Ritchey, J. J. Yuan, G. L. Andriole, W. J. Catalona, T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J. Urol. 150, 1018-1023 (1993).
13. S. Brandau, J. Riemensberger, M. Jacobsen, D. Kemp, W. Zhao, X. Zhao, D. Jocham, T. L. Ratliff, A. Böhle, NK cells are essential for effective BCG immunotherapy. Int. J. Cancer 92, 697-702 (2001).
14. H. Suttmann, J. Riemensberger, G. Bentien, D. Schmaltz, M. Stöckle, D. Jocham, A. Böhle, S. Brandau, Neutrophil granulocytes are required for effective Bacillus Calmette-Guérin immunotherapy of bladder cancer and orchestrate local immune responses. Cancer Res. 66, 8250-8257 (2006).
15. S. Prescott, K. James, T. B. Hargreave, G. D. Chisholm, J. F. Smyth, Intravesical Evans strain BCG therapy: Quantitative immunohistochemical analysis of the immune response within the bladder wall. J. Urol. 147, 1636-1642 (1992).
16. A. Bisiaux, N. Thiounn, M. O. Timsit, A. Eladaoui, H. H. Chang, J. Mapes, A. Mogenet, J. L. Bresson, D. Prié, S. Béchet, C. Baron, C. Sadorge, S. Thomas, E. B. Albert, P. S. Albert, M. L. Albert, Molecular analyte profiling of the early events and tissue conditioning following intravesical bacillus Calmette-Guérin therapy in patients with superficial bladder cancer. J. Urol. 181, 1571- 1580 (2009).
17. D. R. Kelley, T. L. Ratliff, W. J. Catalona, A. Shapiro, J. M. Lage, W. C. Bauer, E. O. Haaff, S. M. Dresner, Intravesical bacillus Calmette- Guérin therapy for superficial bladder cancer: Effect of bacillus Calmette-Guérin viability on treatment results. J. Urol. 134, 48-53 (1985).
18. B. Zbar, Tumor regression mediated by Mycobacterium bovis (strain BCG). Natl. Cancer Inst. Monogr. 35, 341-344 (1972).
19. A. J. Wolf, L. Desvignes, B. Linas, N. Banaiee, T. Tamura, K. Takatsu, J. D. Ernst, Initiation of the adaptive immune response to Mycobacterium tuberculosis depends on antigen production in the local lymph node, not the lungs. J. Exp. Med. 205, 105-115 (2008).
20. W. W. Reiley, M. D. Calayag, S. T. Wittmer, J. L. Huntington, J. E. Pearl, J. J. Fountain, C. A. Martino, A. D. Roberts, A. M. Cooper, G. M. Winslow, D. L. Woodland, ESAT-6-specific CD4 T cell responses to aerosol Mycobacterium tuberculosis infection are initiated in the mediastinal lymph nodes. Proc. Natl. Acad. Sci. U.S.A. 105, 10961-10966 (2008).
21. A. A. Chackerian, J. M. Alt, T. V. Perera, C. C. Dascher, S. M. Behar, Dissemination of Mycobacterium tuberculosis is influenced by host factors and precedes the initiation of T-cell immunity. Infect. Immun. 70, 4501-4509 (2002).
22. C. Durek, E. Richter, A. Basteck, S. Rüsch-Gerdes, J. Gerdes, D. Jocham, A. Böhle, The fate of bacillus Calmette-Guérin after intravesical instillation. J. Urol. 165, 1765-1768 (2001).
23. A. Siatelis, D. P. Houhoula, J. Papaparaskevas, D. Delakas, A. Tsakris, Detection of bacillus Calmette-Guérin (Mycobacterium bovis BCG) DNA in urine and blood specimens after intravesical immunotherapy for bladder carcinoma. J. Clin. Microbiol. 49, 1206-1208 (2011).
24. S. M. Irwin, A. A. Izzo, S. W. Dow, Y. A. Skeiky, S. G. Reed, M. R. Alderson, I. M. Orme, Tracking antigen-specific CD8 T lymphocytes in the lungs of mice vaccinated with the Mtb72F polyprotein. Infect. Immun. 73, 5809-5816 (2005).
25. E. Chan, A. Patel, W. Heston, W. Larchian, Mouse orthotopic models for bladder cancer research. BJU Int. 104, 1286-1291 (2009).
26. J. H. Günther, A. Jurczok, T. Wulf, S. Brandau, I. Deinert, D. Jocham, A. Böhle, Optimizing syngeneic orthotopic murine bladder cancer (MB49). Cancer Res. 59, 2834-2837 (1999).
27. G. Mathé, J. L. Amiel, L. Schwarzenberg, M. Schneider, A. Cattan, J. R. Schlumberger, M. Hayat, F. De Vassal, Active immunotherapy for acute lymphoblastic leukaemia. Lancet 1, 697-699 (1969).
28. D. L. Morton, F. R. Eilber, W. L. Joseph, W. C. Wood, E. Trahan, A. S. Ketcham, Immunological factors in human sarcomas and melanomas: A rational basis for immunotherapy. Ann. Surg. 172, 740-749 (1970).
29. B. Zbar, I. D. Bernstein, H. J. Rapp, Suppression of tumor growth at the site of infection with living Bacillus Calmette-Guérin. J. Natl. Cancer Inst. 46, 831-839 (1971).
30. H. W. Herr, A. Morales, History of bacillus Calmette-Guérin and bladder cancer: An immunotherapy success story. J. Urol. 179, 53-56 (2008).
31. M. A. O'Donnell, Optimizing BCG therapy. Urol. Oncol. 27, 325-328 (2009).
32. Y. Luo, J. Henning, M. A. O'Donnell, Th1 cytokine-secreting recombinant Mycobacterium bovis bacillus Calmette-Guérin and prospective use in immunotherapy of bladder cancer. Clin. Dev. Immunol. 2011, 728930 (2011).
33. M. Peuchmaur, G. Benoit, A. Vieillefond, A. Chevalier, G. Lemaigre, E. D. Martin, A. Jardin, Analysis of mucosal bladder leucocyte subpopulations in patients treated with intravesical Bacillus Calmette-Guérin. Urol. Res. 17, 299-303 (1989).
34. K. K. Huynh, S. A. Joshi, E. J. Brown, A delicate dance: Host response to mycobacteria. Curr. Opin. Immunol. 23, 464-472 (2011).
35. E. R. Rhoades, R. E. Geisel, B. A. Butcher, S. McDonough, D. G. Russell, Cell wall lipids from Mycobacterium bovis BCG are inflammatory when inoculated within a gel matrix: Characterization of a new model of the granulomatous response to mycobacterial components. Tuberculosis 85, 159-176 (2005).
36. W. A. See, G. Zhang, F. Chen, Y. Cao, P. Langenstroer, J. Sandlow, Bacille-Calmette Guérin induces caspase-independent cell death in urothelial carcinoma cells together with release of the necrosis-associated chemokine high molecular group box protein 1. BJU Int. 103, 1714-1720 (2009).
37. G. Marchal, M. Seman, G. Milon, P. Truffa-Bachi, V. Zilberfarb, Local adoptive transfer of skin delayed-type hypersensitivity initiated by a single T lymphocyte. J. Immunol. 129, 954-958 (1982).
38. G. Milon, G. Marchal, M. Seman, P. Truffa-Bachi, A delayed-type hypersensitivity reaction initiated by a single T lymphocyte. Agents Actions 11, 612-614 (1981).
39. R. A. Badalament, H. W. Herr, G. Y. Wong, C. Gnecco, C. M. Pinsky, W. F. Whitmore Jr., W. R. Fair, H. F. Oettgen, A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer. J. Clin. Oncol. 5, 441-449 (1987).
40. T. T. Bui, P. F. Schellhammer, Additional bacillus Calmette-Guérin therapy for recurrent transitional cell carcinoma after an initial complete response. Urology 49, 687-690; discussion 690-1 (1997).
41. T. M. de Reijke, K. H. Kurth, R. J. Sylvester, R. R. Hall, M. Brausi, K. van de Beek, K. E. Landsoght, P. Carpentier; European Organization for the Research and Treatment of Cancer - Genito-Urinary Group, Bacillus Calmette-Guérin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: Results of a European Organization for the Research and Treatment of Cancer- Genito-Urinary Group Phase III Trial (30906). J. Urol. 173, 405-409 (2005).
42. D. R. Kelley, E. O. Haaff, M. Becich, J. Lage, W. C. Bauer, S. M. Dresner, W. J. Catalona, T. L. Ratliff, Prognostic value of purified protein derivative skin test and granuloma formation in patients treated with intravesical bacillus Calmette-Guérin. J. Urol. 135, 268-271 (1986).
43. R. J. Torrence, L. R. Kavoussi, W. J. Catalona, T. L. Ratliff, Prognostic factors in patients treated with intravesical bacillus Calmette-Guérin for superficial bladder cancer. J. Urol. 139, 941-944 (1988).
44. D. L. Lamm, J. I. DeHaven, J. Shriver, M. F. Sarosdy, Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guérin versus intravesical bacillus Calmette-Guérin in superficial bladder cancer. J. Urol. 145, 738-740 (1991).
45. W. Lüftenegger, D. K. Ackermann, A. Futterlieb, R. Kraft, C. E. Minder, P. Nadelhaft, U. E. Studer, Intravesical versus intravesical plus intradermal bacillus Calmette-Guérin: A prospective randomized study in patients with recurrent superficial bladder tumors. J. Urol. 155, 483-487 (1996).
46. T. Shinka, A. Hirano, Y. Uekado, T. Ohkawa, Clinical study of prognostic factors of superficial bladder cancer treated with intravesical bacillus Calmette-Guérin. Br. J. Urol. 66, 35-39 (1990).
47. C. Y. Bilen, K. Inci, I. Erkan, H. Ozen, The predictive value of purified protein derivative results on complications and prognosis in patients with bladder cancer treated with bacillus Calmette-Guérin. J. Urol. 169, 1702-1705 (2003).
48. N. E. Blachère, R. B. Darnell, M. L. Albert, Apoptotic cells deliver processed antigen to dendritic cells for cross-presentation. PLoS Biol. 3, e185 (2005).
49. P. Bousso, A. Casrouge, J. D. Altman, M. Haury, J. Kanellopoulos, J. P. Abastado, P. Kourilsky, Individual variations in the murine T cell response to a specific peptide reflect variability in naive repertoires. Immunity 9, 169-178 (1998).
50. L. Peduto, S. Dulauroy, M. Lochner, G. F. Späth, M. A. Morales, A. Cumano, G. Eberl, Inflammation recapitulates the ontogeny of lymphoid stromal cells. J. Immunol. 182, 5789-5799 (2009).
51. C. Fayolle, E. Deriaud, C. Leclerc, In vivo induction of cytotoxic T cell response by a free synthetic peptide requires CD4+ T cell help. J. Immunol. 147, 4069-4073 (1991).